BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Kostikov A" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis | Bdair H; Kang MS; Ottoy J; Aliaga A; Kunach P; Singleton TA; Blinder S; Soucy JP; Leyton M; Rosa-Neto P; Kostikov A; | 38006502 PERFORM |
| 2 | Dosimetry of [18F]TRACK, the first PET tracer for imaging of TrkB/C receptors in humans | Thiel A; Kostikov A; Ahn H; Daoud Y; Soucy JP; Blinder S; Jaworski C; Wängler C; Wängler B; Juengling F; Enger SA; Schirrmacher R; | 37870640 PERFORM |
| 3 | Radiosynthesis and In Vivo Evaluation of Four Positron Emission Tomography Tracer Candidates for Imaging of Melatonin Receptors | Bdair H; Singleton TA; Ross K; Jolly D; Kang MS; Aliaga A; Tuznik M; Kaur T; Yous S; Soucy JP; Massarweh G; Scott PJH; Koeppe R; Spadoni G; Bedini A; Rudko DA; Gobbi G; Benkelfat C; Rosa-Neto P; Brooks AF; Kostikov A; | 35420022 PERFORM |
| 4 | Development of "[11C]kits" for a fast, efficient and reliable production of carbon-11 labeled radiopharmaceuticals for Positron Emission Tomography. | Jolly D, Hopewell R, Kovacevic M, Li QY, Soucy JP, Kostikov A | 28038410 PERFORM |
| 5 | Effect of (Z)-isomer content on [11C]ABP688 binding potential in humans. | Smart K, Cox SML, Kostikov A, Shalai A, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M | 30607444 CSBN |
| 6 | Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. | Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA | 28894304 PERFORM |
| Title: | Dosimetry of [18F]TRACK, the first PET tracer for imaging of TrkB/C receptors in humans | ||||
| Authors: | Thiel A, Kostikov A, Ahn H, Daoud Y, Soucy JP, Blinder S, Jaworski C, Wängler C, Wängler B, Juengling F, Enger SA, Schirrmacher R | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/37870640/ | ||||
| DOI: | 10.1186/s41181-023-00219-x | ||||
| Publication: | EJNMMI radiopharmacy and chemistry | ||||
| Keywords: | Dosimetry; Positron emission tomography; Tropomyosin receptor kinases; [18F]TRACK; | ||||
| PMID: | 37870640 | Category: | Date Added: | 2023-10-23 | |
| Dept Affiliation: |
PERFORM
1 Jewish General Hospital and Lady Davis Institute for Medical Research, 3755 Chemin de la Cote St. Cathérine, Montreal, Québec, H3T 1E2, Canada. alexander.thiel@mcgill.ca. 2 Department of Neurology & Neurosurgery, McGill Univesrity, Montreal, Canada. alexander.thiel@mcgill.ca. 3 Department of Neurology & Neurosurgery, McGill Univesrity, Montreal, Canada. 4 Brain Imaging Center, Montreal Neurological Institute, Montreal, Canada. 5 Department of Chemistry, McGill University, Montreal, Canada. 6 Jewish General Hospital and Lady Davis Institute for Medical Research, 3755 Chemin de la Cote St. Cathérine, Montreal, Québec, H3T 1E2, Canada. 7 Medical Physics Unit, McGill University, Montreal, Canada. 8 PERFORM Centre Concordia University, Montreal, Canada. 9 Cross Cancer Institute, Medical Isotope Cyclotron Facility, University of Alberta, Edmonton, Canada. 10 Biomedical Chemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 11 Molecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. 12 Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada. 13 Department of Oncology, Division of Oncologic Imaging, University of Alberta, Edmonton, Canada. 14 Medical Faculty, University Bern, Bern, Switzerland. |
||||
Description: |
Background: Reduced expression or impaired signalling of tropomyosin receptor kinases (Trk receptors) are found in a vast spectrum of CNS disorders. [18F]TRACK is the first PET radioligand for TrkB/C with proven in vivo brain penetration and on-target specific signal. Here we report dosimetry data for [18F]TRACK in healthy humans. 6 healthy participants (age 22-61 y, 3 female) were scanned on a General Electric Discovery PET/CT 690 scanner. [18F]TRACK was synthesized with high molar activities (Am = 250 ± 75 GBq/µmol), and a dynamic series of 12 whole-body scans were acquired after injection of 129 to 147 MBq of the tracer. Images were reconstructed with standard corrections using the manufacturer's OSEM algorithm. Tracer concentration time-activity curves (TACs) were obtained using CT-derived volumes-of-interest. Organ-specific doses and the total effective dose were estimated using the Committee on Medical Internal Radiation Dose equation for adults and tabulated Source tissue values (S values). Results: Average organ absorbed dose was highest for liver and gall bladder with 6.1E-2 (± 1.06E-2) mGy/MBq and 4.6 (± 1.18E-2) mGy/MBq, respectively. Total detriment weighted effective dose EDW was 1.63E-2 ± 1.68E-3 mSv/MBq. Organ-specific TACs indicated predominantly hepatic tracer elimination. Conclusion: Total and organ-specific effective doses for [18F]TRACK are low and the dosimetry profile is similar to other 18F-labelled radio tracers currently used in clinical settings. |
